144 related articles for article (PubMed ID: 12200698)
1. Human AML cells in NOD/SCID mice: engraftment potential and gene expression.
Lumkul R; Gorin NC; Malehorn MT; Hoehn GT; Zheng R; Baldwin B; Small D; Gore S; Smith D; Meltzer PS; Civin CI
Leukemia; 2002 Sep; 16(9):1818-26. PubMed ID: 12200698
[TBL] [Abstract][Full Text] [Related]
2. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors.
Feuring-Buske M; Gerhard B; Cashman J; Humphries RK; Eaves CJ; Hogge DE
Leukemia; 2003 Apr; 17(4):760-3. PubMed ID: 12682634
[TBL] [Abstract][Full Text] [Related]
3. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model.
Rombouts WJ; Martens AC; Ploemacher RE
Leukemia; 2000 May; 14(5):889-97. PubMed ID: 10803522
[TBL] [Abstract][Full Text] [Related]
4. Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival.
Monaco G; Konopleva M; Munsell M; Leysath C; Wang RY; Jackson CE; Korbling M; Estey E; Belmont J; Andreeff M
Stem Cells; 2004; 22(2):188-201. PubMed ID: 14990858
[TBL] [Abstract][Full Text] [Related]
5. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
[TBL] [Abstract][Full Text] [Related]
6. Transplantation of human acute myeloid leukemia (AML) cells in immunodeficient mice reveals altered cell surface phenotypes and expression of human endothelial markers.
Henschler R; Göttig S; Junghahn I; Bug G; Seifried E; Müller AM; Fichtner I
Leuk Res; 2005 Oct; 29(10):1191-9. PubMed ID: 15941586
[TBL] [Abstract][Full Text] [Related]
7. Good engraftment of B-cell precursor ALL in NOD-SCID mice.
Baersch G; Möllers T; Hötte A; Dockhorn-Dworniczak B; Rübe C; Ritter J; Jürgens H; Vormoor J
Klin Padiatr; 1997; 209(4):178-85. PubMed ID: 9293448
[TBL] [Abstract][Full Text] [Related]
8. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene.
Rombouts WJ; Blokland I; Löwenberg B; Ploemacher RE
Leukemia; 2000 Apr; 14(4):675-83. PubMed ID: 10764154
[TBL] [Abstract][Full Text] [Related]
9. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
10. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production.
Fusetti L; Pruneri G; Gobbi A; Rabascio C; Carboni N; Peccatori F; Martinelli G; Bertolini F
Cancer Res; 2000 May; 60(9):2527-34. PubMed ID: 10811135
[TBL] [Abstract][Full Text] [Related]
11. Conditions for engraftment of human acute myeloid leukemia (AML) in SCID mice.
Terpstra W; Prins A; Visser T; Wognum B; Wagemaker G; Löwenberg B; Wielenga J
Leukemia; 1995 Sep; 9(9):1573-7. PubMed ID: 7658726
[TBL] [Abstract][Full Text] [Related]
12. Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice.
Bonnet D; Bhatia M; Wang JC; Kapp U; Dick JE
Bone Marrow Transplant; 1999 Feb; 23(3):203-9. PubMed ID: 10084250
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.
Piloto O; Levis M; Huso D; Li Y; Li H; Wang MN; Bassi R; Balderes P; Ludwig DL; Witte L; Zhu Z; Hicklin DJ; Small D
Cancer Res; 2005 Feb; 65(4):1514-22. PubMed ID: 15735040
[TBL] [Abstract][Full Text] [Related]
14. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
[TBL] [Abstract][Full Text] [Related]
15. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
16. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia.
Rombouts EJ; Pavic B; Löwenberg B; Ploemacher RE
Blood; 2004 Jul; 104(2):550-7. PubMed ID: 15054042
[TBL] [Abstract][Full Text] [Related]
17. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
[TBL] [Abstract][Full Text] [Related]
18. Multilineage engraftment in NOD/LtSz-scid/scid mice from mobilized human CD34+ peripheral blood progenitor cells.
Hogan CJ; Shpall EJ; McNiece I; Keller G
Biol Blood Marrow Transplant; 1997 Nov; 3(5):236-46. PubMed ID: 9450918
[TBL] [Abstract][Full Text] [Related]
19. Telomerase is limiting the growth of acute myeloid leukemia cells.
Röth A; Vercauteren S; Sutherland HJ; Lansdorp PM
Leukemia; 2003 Dec; 17(12):2410-7. PubMed ID: 14562114
[TBL] [Abstract][Full Text] [Related]
20. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
